Not all Nano CBDs are created equal. Being Hemp utilizes patented Nano CBD that’s water soluble, encapsulated, and has been clinically proven to improve absorption by 18x versus standard CBD, and 2x greater than other Nano CBDs on the market. (See research study references below.)
When ingested, most CBD molecules, including inferior Nano CBD molecules, do not make it past the harsh, acid-rich environment of the stomach. More than half never reaches the small intestine (and thus the bloodstream), or it passes directly out of the body as waste.
Our Nano encapsulation technology protects the CBD molecules so they can safely reach receptor cells and travel to the sites of action in the body. Being Hemp delivers greater bioavailability to get CBD in and working faster over an extended period of time.
Devinsky, O., M.M. Cilo, H. Cross, J. Fernandez Ruiz, J. French, C. Hill, R. Katz, V. Di Marzo, D. Justras Aswad, W. G. Notcutt, J. Maartinez Orgado, P. J. Robson, B. G. Rohrback, E. Thiele, B. Whalley, and D. Friedman 2014 Cannabidiol Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders Epilepsia 55 6 791 802.
Atsmon J D. Heffetz, L. Deutsch, F. Deutsch, and H, Sacks. 2017. Single dose pharmacokinetics of oral cannabidiol following administration of PTL 101. A new formulation based on gelatin
matrix pellets technology Clin Pharmacol Drug Dev Nov 10 [Epub ahead of print].
Grotenhermen, F. 2003 Clinical pharmacokinetics of cannabinoids J Cannabis Therapeutics 3 1 3 50.
Grotenhermen, F. 2003 Pharmacokinetics and pharmacodynamics of cannabinoids Clin. Pharmacokinet 42 4 327 360.
Hložek, T. L. Uttl, L. Kadeřábek, M. Balíková, E. Lhotková, R. R. Horsley, P. Nováková, K Šíchová, K. Štefková, F Tylš, M Kuchař, and Páleníček T 2017 Pharmacokinetic and behavioural
profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC Eur Neuropsychopharmacol 27 12 1223 1237.
Agurell, S., S. Carlsson, J. E. Lindgren, A. Ohlsson, H. Gillspie, and L. Hollister 1981 Interaction of THC with cannabinol and cannabidiol following oral administration in man Assay of cannabinol and cannabidiol by mass fragmentography Experientia 37 10 1090 1092.
Manini, A. F., G. Yiannoulos, M. M. Bergamaschi, S. Hernandez, R. Olmedo, A. J. Barnes, G. Winkel, R. Sinha, D. Jutras Aswad, M. A. Huestis and Y. I. Hurd 2015 Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans J Addict Med 9 3 204 210.
Ohlsson, A., J. Lindgren, and S. Andersson 1984 Single dose kinetics of cannabidiol in man Pp 219225 in The Cannabinoids Chemical, Pharmacologic, and Therapeutic Aspects 1 st Ed Academic Press, New York, 932 p.
Samara, E., M. Bialer, and R. Mechoulam 1988 Pharmacokinetics of cannabidiol in dogs Drugs Metab Dispos 16 3 469 472.
Zgair, A., J. Lee, J. C. Wong, P. M. Fischer, D. A. Barrett, C. S. Constantinescu, and P. Gershkovich 2015 Effect of long chain triglyceride formulation on the oral bioavailability of cannabidiol American Association of Pharmaceutical Scientists, Annual Meeting, Poster.